Literature DB >> 29362220

Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

Yi-Hsin Lin1,2,3, Ming-Chieh Yang1,4, Ssu-Hsueh Tseng1, Rosie Jiang1, Andrew Yang1, Emily Farmer1, Shiwen Peng1, Talia Henkle1, Yung-Nien Chang1, Chien-Fu Hung5,6, T-C Wu5,6,7,8.   

Abstract

Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-associated buccal tumors. However, they fail to address precancerous phases of disease progression and display tumor microenvironments distinct from those observed in patients. Previously, K14-E6/E7 transgenic mouse models have been used to generate spontaneous tumors. However, the rate of tumor formation is inconsistent, and the host often develops immune tolerance to the viral oncoproteins. We developed a preclinical, spontaneous, HPV16+ buccal tumor model using submucosal injection of oncogenic plasmids expressing HPV16-E6/E7, NRas G12V , luciferase, and sleeping beauty (SB) transposase, followed by electroporation in the buccal mucosa. We evaluated responses to immunization with a pNGVL4a-CRT/E7(detox) therapeutic HPV DNA vaccine and tumor cell migration to distant locations. Mice transfected with plasmids encoding HPV16-E6/E7, NRas G12V , luciferase, and SB transposase developed tumors within 3 weeks. We also found transient anti-CD3 administration is required to generate tumors in immunocompetent mice. Bioluminescence signals from luciferase correlated strongly with tumor growth, and tumors expressed HPV16-associated markers. We showed that pNGVL4a-CRT/E7(detox) administration resulted in antitumor immunity in tumor-bearing mice. Lastly, we demonstrated that the generated tumor could migrate to tumor-draining lymph nodes. Our model provides an efficient method to induce spontaneous HPV+ tumor formation, which can be used to identify effective therapeutic interventions, analyze tumor migration, and conduct tumor biology research. Cancer Immunol Res; 6(3); 305-19. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29362220      PMCID: PMC6056342          DOI: 10.1158/2326-6066.CIR-16-0358

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  78 in total

Review 1.  Squamous cell carcinomas of the head and neck.

Authors:  R J Sanderson; J A D Ironside
Journal:  BMJ       Date:  2002-10-12

2.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

3.  Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.

Authors:  S Merims; X Li; B Joe; P Dokouhaki; M Han; R W Childs; Z-Y Wang; V Gupta; M D Minden; L Zhang
Journal:  Leukemia       Date:  2011-05-13       Impact factor: 11.528

4.  Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.

Authors:  Francesca Gorini; Laura Azzimonti; Gloria Delfanti; Lydia Scarfò; Cristina Scielzo; Maria Teresa Bertilaccio; Pamela Ranghetti; Alessandro Gulino; Claudio Doglioni; Arianna Di Napoli; Miriam Capri; Claudio Franceschi; Federico Caligaris-Cappio; Paolo Ghia; Matteo Bellone; Paolo Dellabona; Giulia Casorati; Claudia de Lalla
Journal:  Blood       Date:  2017-05-02       Impact factor: 22.113

5.  Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model.

Authors:  Katerina Strati; Henry C Pitot; Paul F Lambert
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-07       Impact factor: 11.205

6.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Authors:  Stephen M Wiesner; Stacy A Decker; Jon D Larson; Katya Ericson; Colleen Forster; Jose L Gallardo; Chunmei Long; Zachary L Demorest; Edward A Zamora; Walter C Low; Karen SantaCruz; David A Largaespada; John R Ohlfest
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

9.  Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.

Authors:  S Chellappan; V B Kraus; B Kroger; K Munger; P M Howley; W C Phelps; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

10.  Comparison of HPV DNA vaccines employing intracellular targeting strategies.

Authors:  J W Kim; C-F Hung; J Juang; L He; T Woo Kim; D K Armstrong; S I Pai; P-J Chen; C-T Lin; D A Boyd; T-C Wu
Journal:  Gene Ther       Date:  2004-06       Impact factor: 5.250

View more
  4 in total

1.  Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.

Authors:  Ssu-Hsueh Tseng; Li Liu; Chien-Fu Hung; T -C Wu; Shiwen Peng; Jinhwi Kim; Louise Ferrall
Journal:  J Biomed Sci       Date:  2021-09-13       Impact factor: 12.771

2.  Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.

Authors:  Shiwen Peng; Deyin Xing; Louise Ferrall; Ya-Chea Tsai; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  mBio       Date:  2022-01-04       Impact factor: 7.867

3.  Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7-Expressing Carcinoma in the Cervicovaginal Tract.

Authors:  Talia R Henkle; Brandon Lam; Yu Jui Kung; John Lin; Ssu-Hsueh Tseng; Louise Ferrall; Deyin Xing; Chien-Fu Hung; T-C Wu
Journal:  Cancer Res       Date:  2021-07-02       Impact factor: 12.701

4.  Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis.

Authors:  Deyin Xing; Chien-Fu Hung; Ssu-Hsueh Tseng; Sung-Taek Park; Brandon Lam; Ya-Chea Tsai; Max A Cheng; Emily Farmer
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.